SPL028 / Cybin - LARVOL DELTA

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program (Businesswire) - "Cybin Inc...announced that the United States Patent and Trademark Office has issued two patent grants that offer protection for its deuterated N, N-dimethyltryptamine ('DMT') program. The granted patents protecting the Company’s deuterated DMT program are: United States patent no. 11,771,681, which provides composition of matter protection for certain deuterated analogs of DMT; and United States patent no. 11,773,062, which provides protection for the medical use and the novel, efficient and scalable synthesis of certain analogs of DMT. Cybin’s proprietary novel deuterated DMT compounds, CYB004 and SPL028, are each currently in Phase I clinical trials....Topline data readouts from both studies are expected in Q4 2023."

P1 data • Patent • CNS Disorders • General Anxiety Disorder

Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine. (PubMed, ACS Med Chem Lett) - "The in vitro receptor binding profile of D-DMT was comparable to that of DMT, with the highest affinity at the 5-HT, 5-HT, and 5-HT receptors. D-DMT was therefore the preferred candidate to consider for further evaluation."

Journal • Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Small Pharma Announces Significant Developments In Intellectual Property Portfolio (GlobeNewswire) - "5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions. Small Pharma...today announces an update to its intellectual property ('IP') portfolio, demonstrating significant progress already made by the Company in 2023."

Patent • CNS Disorders • Depression • Major Depressive Disorder